Unaudited financial results for the quarter and half year ended 30.09.2025

Net loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹9.98

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+1.3% vs market

Pharmaceuticals peers, median of 157sector+0.0%+1.2% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2-0.1+1.3+0.0+1.2

Next day

+7.2+0.5+6.7-0.1+7.4

+7.8-0.3+8.1-0.9+8.7

+3.5-0.5+4.0-1.4+4.9

+3.4-0.8+4.2-1.6+5.0

+2.6-2.3+4.9-2.3+4.9

-1.8-2.8+1.0-3.1+1.3

15d

-0.4-4.9+4.5-3.6+3.2

-3.9-4.7+0.8-4.4+0.5

-9.8-7.7-2.1-5.6-4.2

-16.0-7.8-8.2-10.3-5.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Decipher Labs Limited (formerly Combat Drugs Limited) reported its unaudited results for Q2 and H1 FY26 (ended Sept 30, 2025). On a standalone basis, H1 FY26 revenue rose sharply to Rs 93.45 lakhs from Rs 36.72 lakhs in H1 FY25, while the loss narrowed to Rs 5.96 lakhs from Rs 18.70 lakhs. However, on a consolidated basis, revenue fell about 46% to Rs 723.74 lakhs from Rs 1,330.77 lakhs, and the company swung to a loss of Rs 340.66 lakhs compared to a small profit in H1 FY25. Net cash used in operating activities was Rs 0.67 lakhs standalone and Rs 218.87 lakhs consolidated. The board also appointed Mr. Dalavath Amar Singh as an Additional Executive Director for two years at Rs 6 lakhs per annum. Auditor Ramanatham & Rao issued an unqualified review report.

Likely market impact

Mixed picture for shareholders — standalone numbers show improving revenue and shrinking losses, but the consolidated business (driven by subsidiaries in the USA and Bahrain) deteriorated sharply with revenue halving and a large loss. Combined with negative operating cash flows on both bases, this is a cautious signal for the stock and highlights continued volatility.